Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Induction Treatment With Anti-CD20 Plus Hyper-CVAD and Methotrexate/Cytarabine Followed by Consolidation Treatment With Y90 Ibritumomab-Tiuxetan in Patients With Mantle Cell Lymphoma

NCT00505232 is registered in ClinicalTrials.gov with CABYC as lead sponsor.

NCT NCT00505232
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00505232 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Induction Treatment With Anti-CD20 Plus Hyper-CVAD and Methotrexate/Cytarabine Followed by Consolidation Treatment With Y90 Ibritumomab-Tiuxetan in Patients With Mantle Cell Lymphoma
Lead sponsor
CABYC
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2006
Completion date
May 31, 2011
Enrollment
30 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

mantle cell lymphoma